Materials today. Bio2026ReviewDrug Delivery
Shan Q, Zheng W, Yao W, Bai Y, Ding W, Wang J, Et Al.
Alzheimer's disease (AD) is an irreversible neurodegenerative disease that has thus far suffered from unsatisfactory therapeutic outcomes. Despite ongoing research into AD pathogenesis and related drugs, few disease-modifying therapies are currently available. Moreover, efficient drug delivery is significantly…
Read the article →Clinical and experimental vaccine research2026ReviewDrug Delivery
Shahab Ms, Azizuddin S, Aslam M, Haque Mw, Ahsan Mn, Snigdha Nt, Et Al.
Biomimetic nanoparticles (BMNPs) have emerged as promising platforms for cancer vaccines and immunotherapy by combining nanoscale delivery systems with biological interfaces derived from cells or extracellular vesicles (EVs). Their therapeutic behavior is influenced by the biological source, surface composition…
Read the article →Advanced pharmaceutical bulletin2026ReviewDrug Delivery
Hari M, Subramony A, Dwivedi D, Krishnan Rs, Damodaran A, Nair Sc
Treatment for Parkinson's disease (PD) faces two significant challenges: first, the blood-brain barrier (BBB) and second, a therapeutic strategy that alleviates symptoms instead of stopping the disease progression. The BBB prevents over 98% of small-molecule drugs, leaving neuroprotective options mostly inaccessible…
Read the article →Advanced pharmaceutical bulletin2026ReviewDrug Delivery
Ainurofiq A, Rosalin Ea, Istiyono Ms, Maharani Na, Fauzy R, Sugiharti Sn, Et Al.
Chronic Obstructive Pulmonary Disease (COPD) is a condition that poses major challenges in therapeutic management, primarily due to the limitations of conventional inhalation methods in achieving optimal drug deposition and maintaining therapeutic effects over a long period. Inhalable nanomedicine has emerged as an…
Read the article →Nanomedicine (London, England)2026ReviewDrug Delivery
Malak Q, Mazumder R, Rani A, Dogra A
Retinoblastoma is an aggressive intraocular tumor in children, with a major underlying pathogenesis driven by mutations in the RB1 gene. Despite advances in management, current treatments, including systemic chemotherapy, focal therapies, radiotherapy, and enucleation, are limited by systemic toxicity, ocular…
Read the article →Current drug targets2026ResearchDrug Delivery
Sharma S, Nag P, Vij K, Kalra A, Goel K
Neurological problems are among the world's most significant health issues. Many conditions are considered incurable because current treatments cannot effectively cross the Blood-Brain Barrier (BBB) to exert pharmacological effects. Nanomedicine utilizing various nanoparticles offers a distinct therapeutic approach…
Read the article →International journal of biological macromolecules2026ResearchDrug Delivery
Lin Zi, Yeh Tc, Sun Gc, Chen Yy, Cheng Pw
Chitosan-based biological macromolecules provide a versatile platform for ocular drug delivery, but their hydrophilic nature limits the encapsulation and sustained release of hydrophobic therapeutics. Here, we designed oleic acid-functionalized chitosan nanoparticles (OA-CS NPs) with tunable hydrophobicity by varying…
Read the article →Journal of orthopaedic translation2026ReviewNon-viral Gene DeliveryDrug Delivery
Chen X, Sun J, Xie W, Arthur Vithran Dt, Zhang Q, Rosenholm Jm, Et Al.
Degenerative musculoskeletal diseases (DMDs) are a group of chronic conditions characterized by the progressive deterioration of tissue structure and function, primarily affecting the articular cartilage, bones, tendons, and ligaments. With global aging populations, the rising prevalence of these disorders presents a…
Read the article →Pharmaceutics2026ReviewDrug Delivery
Ban M, Zhao S, Liu Z, Zhao L
Cancer remains a major global health challenge, and nanoparticle-based drug delivery systems have emerged as a promising strategy for targeted cancer therapy. However, clinical translation is still limited by an incomplete understanding of how nanoparticles navigate the tumor microenvironment (TME) throughout the…
Read the article →Molecular therapy. Oncology2026ReviewNon-viral Gene DeliveryDrug Delivery
Bedada At, Genet S
Cancer remains a formidable global health challenge, representing the second leading cause of mortality worldwide. In 2023, there were approximately 18.5 million new cancer cases and over 10 million deaths globally, with projections estimating 30.5 million new cases and 18.6 million deaths annually by 2050. In the…
Read the article →The Journal of pharmacy and pharmacology2026ReviewDrug Delivery
Dubey S, Prakash S, Deshwal Rk, Dwivedi M
Cancer remains a major global health challenge despite significant advances in diagnosis and treatment. Conventional therapies, including chemotherapy, radiotherapy, and surgery, are frequently constrained by non-specific drug distribution, systemic toxicity, multidrug resistance (MDR), and limitations in early tumor…
Read the article →ACS nanoscience Au2026ResearchNon-viral Gene DeliveryDrug Delivery
Rogado Mt, Wang A, Zeng S, Wang Z, Burda C
Lipid nanoparticles (LNPs) have risen to the forefront of modern therapeutics by enabling the clinical success of COVID-19 mRNA vaccines. In order for them to function as drug delivery vesicles, LNPs must have scalable, tunable, and targeted nanoscale platforms whose strengths in versatility, performance, and…
Read the article →International journal of nanomedicine2026ReviewDrug Delivery
Gharatape A, Alikhanian A, Verdi J, Choonara Ye, Faridi-Majidi R
Although therapeutic opportunities beyond the scope of either field alone are offered by the combination of immune cell treatment and nanotechnology, a dominant nanoparticle design for immune-cell engineering has not been yielded by two decades of research. Here, it is contended that this lack of advancement is the…
Read the article →Nature Communications2023ResearchNon-viral Gene Delivery
Yue Wang, Shi-Kun Zhou, Yan Wang, Zi-Dong Lu, Yue Zhang, Cong-Fei Xu, Jun Wang
PD-1/PD-L1 blockade therapy is successful but often yields poor benefits due to insufficient T-cell infiltration and low intratumoral concentrations of PD-1/PD-L1 inhibitors. While strategies exist to increase either T-cell recruitment or inhibitor delivery, none actively recruit T cells while achieving…
Read the article →International Journal of Nanomedicine2023ResearchNon-viral Gene Delivery
Hannah J Vaughan, Camila G Zamboni, Kathryn M Luly, Ling Li, Kathleen L Gabrielson, Laboni F Hassan, Nicholas P Radant, Pranshu Bhardwaj, Florin M Selaru, Martin G Pomper, Jordan J Green
Hepatocellular carcinoma (HCC) has limited treatment options, with modest survival after systemic chemotherapy or transarterial chemoembolization (TACE). Gene therapies hold promise for treating HCC, but delivery remains a critical hurdle. While poly(beta-amino ester) (PBAE) nanoparticles have shown efficacy in…
Read the article →Nature Communications 14, 345 (2023ResearchNon-viral Gene Delivery
Xuexiang Han, Ningqiang Gong, Lulu Xue, Margaret M. Billingsley, Rakan El-Mayta, Sarah J. Shepherd, Mohamad-Gabriel Alameh, Drew Weissman, Michael J. Mitchell
Liver fibrosis has no approved antifibrotic therapies. Activated hepatic stellate cells (HSCs) drive fibrosis by producing collagen, and HSP47 is a key collagen chaperone in these cells. Targeted delivery of siRNA to activated HSCs remains challenging, so a ligand-tethered LNP platform was developed to deliver RNA…
Read the article →2023ReviewNon-viral Gene Delivery
Pinto Is, Cordeiro Ra, Faneca H
CAR T cell therapy is FDA/EMA-approved for B cell malignancies and multiple myeloma, but manufacturing relies on viral vectors—associated with safety concerns, high cost, and production challenges—or electroporation, which can be highly cytotoxic. Nanosystems may offer a safer, cost-effective alternative, but T cells…
Read the article →Acta Pharmaceutica Sinica B2022ReviewNon-viral Gene Delivery
Yingping Zeng, Sufen Li, Shufen Zhang, Li Wang, Hong Yuan, Fuqiang Hu
Cancer immunotherapy is limited by tumour heterogeneity, immune cell disability, immunosuppressive tumour microenvironment (TME), and systemic immune toxicity. Cell membrane-coated nanoparticles (CMCNs) offer a biomimetic delivery strategy that inherits source-cell functions—immune evasion, tumour targeting, and…
Read the article →Frontiers in Oncology2022ReviewNon-viral Gene Delivery
Tianqing Xin, Li Cheng, Chuchao Zhou, Yimeng Zhao, Zhenhua Hu, Xiaoyan Wu
CAR-T cell therapy has shown impressive success in haematological malignancies, but systemic toxicity (CRS, ICANS, on-target/off-tumour effects) and the complex, costly, individualized manufacturing process of autologous CAR-T cells hinder broader application. Universal allogeneic CAR-T cells have encountered safety…
Read the article →Science Advances2022ReviewNon-viral Gene Delivery
Ann E. Metzloff, Margaret M. Billingsley, Michael J. Mitchell
mRNA vaccines have entered global use, but delivering mRNA to T cells in vivo remains challenging because T cells are non-phagocytic, reside largely in lymphoid tissues, and intravenously administered lipid nanoparticles (LNPs) tend to accumulate in the liver. There is a need for precise, scalable strategies to…
Read the article →Science2022ResearchNon-viral Gene Delivery
Joel G. Rurik, István Tombácz, Amir Yadegari, Pedro O. Méndez Fernández, Swapnil V. Shewale, Li Li, Toru Kimura, Ousamah Younoss Soliman, Tyler E. Papp, Ying K. Tam, Barbara L. Mui, Steven M. Albelda, Ellen Puré, Carl H. June, Haig Aghajanian, Drew Weissman, Hamideh Parhiz, Jonathan A. Epstein
Fibrosis affects millions of people with cardiac disease and contributes to heart failure. While adoptive transfer of CAR T cells targeting fibroblast activation protein (FAP) has shown promise in reducing cardiac fibrosis, conventional CAR T cells persist for months to years and could cause chronic off-target…
Read the article →Science Advances2022ResearchNon-viral Gene Delivery
Rasheid Smith, Emad I. Wafa, Sean M. Geary, Kareem Ebeid, Suhaila O. Alhaj-Suliman, Aliasger K. Salem
Cancer vaccines as monotherapies have displayed limited clinical success due to the immunosuppressive tumour microenvironment (TME). Nanoscale formulations can enhance vaccine efficacy by combating TME immunosuppression, but there is a need for novel adjuvant formulations that can be combined with therapeutic cancer…
Read the article →Journal of Controlled Release 344 (2022ResearchNon-viral Gene Delivery
Hamideh Parhiz, Jacob S. Brenner, Priyal N. Patel, Tyler E. Papp, Hamna Shahnawaz, Qin Li, Ruiqi Shi, Marco E. Zamora, Amir Yadegari, Oscar A. Marcos-Contreras, Ambika Natesan, Norbert Pardi, Vladimir V. Shuvaev, Raisa Kiseleva, Jacob W. Myerson, Thomas Uhler, Rachel S. Riley, Xuexiang Han, Michael
Nucleoside-modified mRNA lipid nanoparticle (modmRNA-LNP) technology is clinically successful, but its behaviour in pre-existing inflammatory or immune-challenged conditions is poorly characterised. This gap raises the risk of adverse effects when modmRNA-LNPs are administered to patients with ongoing inflammation…
Read the article →Journal of Controlled Release 341 (2022ResearchNon-viral Gene Delivery
Kelsey L. Swingle, Margaret M. Billingsley, Sourav K. Bose, Brandon White, Rohan Palanki, Apeksha Dave, Savan K. Patel, Ningqiang Gong, Alex G. Hamilton, Mohamad-Gabriel Alameh, Drew Weissman, William H. Peranteau, Michael J. Mitchell
Congenital protein deficiencies often begin irreversible pathology in utero, but postnatal treatments are limited. In utero mRNA delivery could enable protein replacement before disease onset, yet LNP stability in fetal amniotic fluid and how it affects mRNA delivery had not been previously investigated. LNP A12 was…
Read the article →